CAR T-Cell Combination Approaches for Complete Immune Reset
- Distinguishing diseases driven by CD20+ B-Cells from those driven by plasma cells to inform the choice of alternative targets such as BCMA and CD38
- Harnessing base editing to enable CAR T-cell combination therapies for B-cell targeting and beyond
- Discussing the possibility of B-cell reconstitution, focusing on whether the new B-cell compartment is “reset” to a non-autoreactive state